• 17-AAG (Tanespimycin): Reliable Cell Assays

  2026-09-14

  A scenario-based guide to improving viability, proliferation, and cytotoxicity experiments with 17-AAG (Tanespimycin), SKU A4054. It connects HSP90 biology with formulation control, dose-response design, endpoint interpretation, and practical product selection for reproducible cancer research.

• GW 4869: Exosome Workflow for Lupus Nephritis

  2026-09-13

  GW 4869 hydrochloride hydrate provides a practical pharmacologic gate for testing whether neutral sphingomyelinase-dependent vesicle release drives endothelial injury. This workflow combines donor-cell perturbation, extracellular vesicle normalization, HMGB1/TRIM27 pathway testing, and controls that distinguish exosome effects from broader sphingolipid signaling.

• Necrostatin 2 (Nec-2) Workflow for Necroptosis

  2026-09-12

  Necrostatin 2 (Nec-2) provides a temporally controlled way to investigate programmed necrotic cell death, RIPK2 signaling, and membrane-injury phenotypes. This practical guide connects Nec-2 dose optimization with the Kupffer-cell and plasma-membrane findings reported in Listeria research, while clearly separating established evidence from exploratory applications.

• Blebbistatin for Causal Cell Mechanics Imaging

  2026-09-11

  Use (±)-Blebbistatin to connect non-muscle myosin II activity with migration, adhesion, and morphology while preserving a reversible live-cell workflow. Inspired by panoramic cardiac mapping, the approach pairs mechanical perturbation with registered structure–function imaging for stronger causal interpretation.

• Neuritin, ER Stress, and NF-κB After SAH

  2026-09-11

  The reference study identifies coordinated endoplasmic reticulum stress pathways as drivers of NF-κB-linked neuroinflammation and neuronal apoptosis during early brain injury after subarachnoid hemorrhage. Its central contribution is showing that neuritin overexpression suppresses these convergent pathways, providing a mechanistic framework for evaluating neuroprotective interventions in SAH.

• Native-Membrane Proteoforms and Drug Selectivity

  2026-09-10

  A 2025 Nature Chemistry study introduces native top-down mass spectrometry for connecting membrane-protein modifications with ligand interactions in intact lipid environments. Using retinal rhodopsin, G proteins, and PDE6, the authors show that proteoform identity and lipidation can shape drug binding and off-target selectivity.

• Native Proteoform Interactions for Drug Targeting

  2026-09-10

  This Nature Chemistry study introduces native top-down mass spectrometry for resolving membrane-protein proteoforms and their ligand interactions without first removing the native lipid environment. Its analysis of rhodopsin, G-protein lipidation, and PDE6 binding by Vardenafil and sildenafil shows why modification-resolved pharmacology can reveal off-target behavior missed by conventional assays.

• Vardenafil HCl Trihydrate in PDE5 Research

  2026-09-09

  Vardenafil HCl Trihydrate gives researchers a high-potency, selective tool for connecting PDE5 inhibition with cGMP signaling, smooth muscle relaxation, and functional erectile dysfunction models. Its use can be extended into proteoform-aware workflows that compare soluble enzyme assays with native membrane and PDE6 counter-screening.

• Sodium Orthovanadate in Translational Signaling

  2026-09-09

  A mechanistic and strategic guide to using Sodium Orthovanadate and Na3VO4 for phosphorylation state preservation, insulin-signaling studies, kinase assays, and translational assay design.

• O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia

  2026-09-08

  The reference study identifies an O-GlcNAc–HUWE1–TfR1 pathway that connects protein modification with iron uptake, ferroptosis, and trophoblast syncytialization in preeclampsia. Its combination of O-GlcNAc modification proteomics, mechanistic validation, trophoblast models, and mouse experiments provides a framework for testing how placental stress is regulated.

• Ceftolozane/Tazobactam: Mechanism, Evidence, and Limits

  2026-09-08

  The reference review presents ceftolozane/tazobactam as an engineered antipseudomonal cephalosporin–β-lactamase inhibitor combination designed to preserve activity against important resistant Gram-negative pathogens. Its key practical contribution is linking PBP pharmacology, β-lactamase coverage, pharmacokinetic/pharmacodynamic targets, renal dosing, and clinical-trial evidence into a framework for evaluating resistant-infection therapies.

• Vernakalant Hydrochloride: AF Assay Workflows

  2026-09-07

  Vernakalant Hydrochloride supports translational studies that connect atrial ion-channel pharmacology with rapid conversion of atrial fibrillation. This guide presents exposure-aware cell assays, PK-linked interpretation, workflow controls, and troubleshooting strategies for RSD1235 research.

• Ridaforolimus for mTOR Cancer Research

  2026-09-07

  Ridaforolimus, also called Deforolimus or MK-8669, gives researchers a nanomolar tool for connecting mTOR pathway inhibition with proliferation, protein synthesis, VEGF output, and treatment response. This guide translates its reported activity into practical cancer-cell workflows while showing how machine-learning-derived senolytic research can inform assay design without overstating the evidence.

• Pexidartinib: From Microglia to Tumor Macrophages

  2026-09-05

  Pexidartinib (PLX3397) offers translational researchers a selective chemical entry point into CSF1R biology, connecting macrophage control in oncology with broader principles of myeloid regulation. This article interprets recent evidence on microglial activation and seizure susceptibility to define a disciplined strategy for tumor microenvironment studies, including experimental validation, competitive positioning, and translational limits.

• Wnt agonist 1: Practical Pathway Activation

  2026-09-04

  Wnt agonist 1, also known as BML-284, provides a controllable small-molecule entry point for β-catenin/TCF signaling studies. This guide connects dose-response design, differentiation and developmental assays, and a hypothesis-driven cancer workflow to practical handling and troubleshooting decisions.

7938 records 1/530 page Next 12345 下5页 Last page